Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-28T22:28:19.016Z Has data issue: false hasContentIssue false

Tipo de antipsicótico y correlatos de la interrupción del tratamiento de antipsicóticos en el tratamiento ambulatorio de la esquizofrenia

Published online by Cambridge University Press:  12 May 2020

Joseph María Haro
Affiliation:
Unidad de Investigación y Desarrollo, Sant Joan de Déu-Serveis de Salut Mental, Dr. Antoni Pujades 42, 08030, Sant Boi, Barcelona, España
Diego Novick
Affiliation:
European Health Outcomes Research, Eli Lilly and Company Limited, Windlesham, Surrey, Reino Unido
Mark Belger
Affiliation:
European Commercialization Statistics, Eli Lilly and Company Limited, Windlesham, Surrey, Reino Unido
Peter B. Jones
Affiliation:
Universidad de Cambridge, Addenbrooke's Hospital, Cambridge, Reino Unido
Get access

Resumen

Se analizó el mantenimiento de la medicación antipsicótica y los factores que influyen en él utilizando datos del estudio SOHO, un gran estudio observacional de la evolucion del tratamiento de antipsicóticos para la esquizofrenia en Europa. Se analizó a un total de 7.186 pacientes adultos en el entorno ambulatorio en los que se inició o cambió la medicación antipsicótica y a quienes se prescribió sólo un antipsicótico después de la vísita de linea de base. El mantenimiento de la medicación a los 12 meses variaba con el tipo de antipsicótico prescrito, siendo más alto con la clozapina (79,5%) y la olanzapina (77%) y más bajo con la quetiapina (51,4%) y la amisulprida (58,2%). El análisis de regresión logística mύltiple demostró que el tipo de antipsicótico prescrito en la línea de base era el predictor más importante del mantenimiento de la medicación. La dependencia de alcohol, el consumo de estabilizadores del estado de ánimo, el ingreso obligatorio o la detención en los 6 meses anteriores, la mayor gravedad clínica y el cambio de la medicación antipsicótica debido a falta de eficacia en la línea de base predecían una frecuencia mayor de interrupción de la medicación en los 12 meses posteriores. Por contraste, el mantenimiento de la medicación era más alto entre los pacientes que no habían recibido ningύn tratamiento en la línea de base, eran activos socialmente o habían perdido la líbido en la linea de base. Los hallazgos de este estudio se deben interpretar conservadoramente a causa de su diseño observacional no distribuido al azar. © 2005 Elsevier SAS. Todos los derechos reservados.

Type
Artículo original
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aizenberg, DZemishlany, ZDorfman-Etrog, PWeizman, A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137–41.Google ScholarPubMed
Barak, YWittenberg, NNaor, SKutzuk, DWeizman, A. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry 1999;40:320–5.CrossRefGoogle ScholarPubMed
Basile, VSMasellis, MMclotyre, RSMeltzer, HYLieberman, JAKennedy, JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62(Suppl 23):4566.Google ScholarPubMed
Beasley, CM Jr.Sutton, VKHamilton, SHWalker, DJDossenbach, MTaylor, CC, et al.A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582–94.CrossRefGoogle ScholarPubMed
Chakos, MLieberman, JHoffman, EBradford, DSheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment- resistant schizophrenia: a review and meta-analysis of randomized triais. Am J Psychiatry 2001;158:518–26.CrossRefGoogle Scholar
Csemansky, JGMahmoud, RBrenner, R. Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:1622.CrossRefGoogle Scholar
Cutler, AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28(Suppl l):6982.CrossRefGoogle ScholarPubMed
Davis, JMChen, N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):2433.Google Scholar
Davis, JMChen, N. Old versus new: weighing the evidence between the first-and second-generation antipsychotics. Eur Psychiatry 2005;20:714.CrossRefGoogle ScholarPubMed
Droulout, TLiraud, FVerdoux, H. Relationships between insight and medication adherence in subjects with psychosis. Encephale 2003;29(5):430–7.Google ScholarPubMed
Glick, IDBerg, PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65–8.CrossRefGoogle ScholarPubMed
Green, AICanuso, CMBrenner, MJWojcik, JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003;26:115–39.CrossRefGoogle ScholarPubMed
Guy, G. Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Menta Health; 1976.Google Scholar
Haro, JMEdgell, ETFrewer, PAlonso, J, Jones PB on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 2003;107(Suppl 416):19.CrossRefGoogle Scholar
Haro, JMEdgell, ETJones, PBAlonso, JGavart, SGregor, KJ, et al.The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222–32.CrossRefGoogle ScholarPubMed
Haro, JMEdgell, ENovick, DAlonso, JKennedy, LJones, P, et al.Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111:220 31.CrossRefGoogle ScholarPubMed
Haro, JMKamath, SAOchoa, SNovick, DRele, KFargas, A, et al.The clinical global impression schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003;107:16 23 (Suppl 416).CrossRefGoogle Scholar
Lambert, MHaro, JMNovick, DEdgell, ETKennedy, LRatcliffe, M, et al.Olanzapine versus other antipsychotics in actual outpatient settings: 6-month safety results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111:232–43.CrossRefGoogle Scholar
Marder, SRGlynn, SMWirshing, WCWirshing, DARoss, DWidmark, C, et al.Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160: 1405–12.CrossRefGoogle ScholarPubMed
Perkins, DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–8.CrossRefGoogle ScholarPubMed
Raja, MAzzoni, A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry 2003;18:70–6.CrossRefGoogle ScholarPubMed
Robinson, DGWoomer, MGAlvir, JMBilder, RMHinrichsen, GALiebemman, JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209–19.CrossRefGoogle ScholarPubMed
Santarlasci, BMessori, A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003;37:556–63.CrossRefGoogle ScholarPubMed
Sohohm, BLublin, H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand 2003;107:344–50.Google Scholar
Stroup, TSMcEvoy, JPSwartz, MSByerly, MJGlick, IDCanive, JM, et al.The National Institute of Mental Health Clinical Antipsychotic Triais of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:1531.CrossRefGoogle Scholar
Tavcar, RDemovsek, MZZvan, V. Choosing antipsychotic maintenance therapy—a naturalistic study. Pharmacopsychiatry 2000;33:6671.CrossRefGoogle ScholarPubMed
Weiss, KASmith, TEHull, JWPiper, ACHuppert, JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002;28:341–9.CrossRefGoogle ScholarPubMed
Lieberman, JAStroup, TSMcEvoy, JPSwartz, MSRosenheck, RAPerkins, DO, et al., Clinical Antipsychotic Triais of Intervention Effectiveness (CATIE) Investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med 2005;353:1209–23.CrossRefGoogle Scholar